Edwards Lifesciences (EW) Cash & Equivalents (2009 - 2026)

Edwards Lifesciences has reported Cash & Equivalents for 18 years, with the latest figure at $2.9 billion in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 11.19% year-over-year to $2.9 billion in Q2 2026; TTM through Jun 2026 was $2.9 billion, a 11.19% decrease from a year earlier, with the FY2025 full-year figure at $2.9 billion, down 3.52% from the prior year.
• Cash & Equivalents was $2.9 billion for Q2 2026 at Edwards Lifesciences, up from $2.4 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $3.7 billion in Q3 2024, with the low at $769.0 million in Q4 2022.
• Average Cash & Equivalents over 5 years is $2.0 billion, with a median of $1.5 billion recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents jumped 168.94% in 2024, then slipped 26.95% in 2025.
• Over 5 years, Cash & Equivalents stood at $769.0 million in 2022, then surged by 47.24% to $1.1 billion in 2023, then soared by 168.94% to $3.0 billion in 2024, then slipped by 3.52% to $2.9 billion in 2025, then fell by 1.07% to $2.9 billion in 2026.
• The last three Cash & Equivalents figures came in at $2.9 billion (Q2 2026), $2.4 billion (Q1 2026), and $2.9 billion (Q4 2025), per Business Quant data.